Piribedil-Induced Sleep Attacks in Patients Without Parkinson Disease: A Case Series

@article{Gouraud2011PiribedilInducedSA,
  title={Piribedil-Induced Sleep Attacks in Patients Without Parkinson Disease: A Case Series},
  author={Aurore Gouraud and Anne Millaret and Jacques Descotes and Thierry Vial},
  journal={Clinical Neuropharmacology},
  year={2011},
  volume={34},
  pages={104-107}
}
Background: Sleep attacks were initially described in 1999 in patients with Parkinson disease (PD) treated by dopamine agonists (DAs). Because the respective role of DAs or PD-induced excessive daytime sleepiness is still unclear, reports of sleep attacks in non-PD patients treated with DA would support the specific role of these drugs. Piribedil, a nonergot dopamine D2/D3 agonist with alpha2-noradrenergic properties, is indicated in the treatment of PD as well as in patients with circulatory… 
Sleep Attacks in Patients With Parkinson's Disease on Dopaminergic Medications: A Systematic Review
TLDR
A systematic literature review found conflicting results on whether sleep attacks in PD resemble narcolepsy, and the most effective management strategies were dose reduction and discontinuation of the offending drugs.
Piribedil: sleep attacks, also in patients without Parkinson's disease.
  • Psychology, Medicine
    Prescrire international
  • 2013
TLDR
A study based on the French national pharmacovigilance database identified and analysed 7 reports of sleep attacks attributed to piribedil in patients without Parkinson's disease and indicates that piribingil has a direct role in the onset of sleep attack.
Excessive daytime sleepiness and unintended sleep episodes associated with Parkinson's disease.
TLDR
The issues of excessive daytime sleepiness and unintended sleep episodes in patients with Parkinson's disease (PD) are looked at and the reasons why patients might suffer from these symptoms are explored, and what steps could be taken to manage them.
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease
TLDR
Piribedil was considered in the last Movement Disorder Society Evidence-Based Medicine review as “efficacious” and “clinically useful” for the symptomatic treatment of PD, either as monotherapy or in conjunction with levodopa, in non-fluctuating early PD patients.
Piribedil and pathological gambling in six parkinsonian patients.
TLDR
Despite piribedil is commercially available in only a few countries, it should be considered in the differential diagnosis of PG in patients with PD.
Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology
  • J. Borovac
  • Medicine, Biology
    The Yale journal of biology and medicine
  • 2016
TLDR
The goal of this review is to provide a comprehensive, up-to-date overview of DA therapeutic modalities for PD.
The Effects of Dopamine Receptor Agonists on the Sleep-Wake Cycle
TLDR
The current knowledge regarding the role of DA receptor agonist in sleep modulation is highlighted and compounds that bind and activate DA receptors are significant means for the study of mechanism of action of DA controlling biological phenomena such as sleep.
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Sleep attacks in patients taking dopamine agonists: review
TLDR
Insufficient data is available to provide effective guidelines for prevention and treatment of sleep events in patients taking dopamine agonists for Parkinson's disease, and Prospective population based studies are needed to provide this information.
Piribedil‐induced sleep attacks in Parkinson's disease
  • E. Tan
  • Psychology, Medicine
    Fundamental & clinical pharmacology
  • 2003
TLDR
Details of the clinical characteristics of Piribedil‐induced sleep attacks in patients with Parkinson's disease taking the newer dopamine agonists pramipexole and ropinirole are provided.
Excessive daytime sleepiness in parkinsonism.
  • I. Arnulf
  • Psychology, Medicine
    Sleep medicine reviews
  • 2005
Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome.
Restless leg syndrome, dopamine agonists and sleep attacks
TLDR
The temporal relationship of this phenomenon to the use of cabergoline strongly suggested that sleep attacks were a drug-related side-effect.
Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study
TLDR
The present work suggests that sleep attacks are a common side effect of all dopamine agonist treatment, and underlines the major contributing role of autonomic failure followed by dopamine agonists in the occurrence of such an event.
A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France
TLDR
EDS is common in ambulatory patients with PD and is a major risk factor for dozing and for SOS episodes behind the wheel in patients who drive, and risk factors for EDS were male gender, reduced activity of daily living, and high daily levodopa equivalent dosage.
Sleep disturbances in patients with parkinsonism
TLDR
Improving night-time motor control by overnight treatment with levodopa, transdermal or long-acting dopamine agonists, or bilateral subthalamus stimulation, can improve sleep continuity in Parkinson's disease.
‘Sleep Attacks’ or ‘Unintended Sleep Episodes’ Occur with Dopamine Agonists
TLDR
The issue of ‘ sleepiness’ or ‘sleep attacks’ in PD should be routinely checked in all patients with PD and indirectly assessed by using either the ESS or the recently introduced Parkinson’s Disease Sleep Scale.
Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects.
TLDR
It is shown that a single oral dose of pramipexole induces sleepiness as assessed by MSLT in healthy young subjects, independent of disease-related sleep dysfunction.
...
1
2
3
...